Is CLYM or CNTA more undervalued in 2026?

CirclFi compares Climb Bio, Inc. (CLYM) and Centessa Pharmaceuticals plc (CNTA) using 13 institutional-grade valuation models. CLYM has a Quality of Company score of 4.1/10 while CNTA scores 5.9/10.

Which is a better buy — CLYM or CNTA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CLYM and CNTA valuations compare?

CLYM at $11.34 and CNTA at $39.81 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CLYM vs CNTA Valuation Comparison 2026 — Intrinsic Value Analysis

CLYM

Biotechnology

Climb Bio, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$11.34

Last close

Models

7/13

Active

CNTA

Biotechnology

Centessa Pharmaceuticals plc

Quality

5.9

out of 10

Value Trap

SAFE

Price

$39.81

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	CLYM Fair Value	CLYM Upside	CNTA Fair Value	CNTA Upside
Bayesian DCF	Intrinsic	$3.12	-72.5%	$11.91	-70.1%
Earnings Power Value	Intrinsic	—	—	$16.41	-58.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.84	-92.6%	$0.49	-98.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CLYM vs CNTA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CLYM vs CNTA — Which Stock Is More Undervalued?

CNTA scores higher with a 5.9/10 quality rating vs CLYM's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Climb Bio, Inc. (CLYM) and Centessa Pharmaceuticals plc (CNTA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CLYM currently trades at $11.34 with a QOC of 4.1/10, while CNTA trades at $39.81 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).